comparemela.com

Page 6 - Ableson Tyrosine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 201 Trial Evaluating IkT-148009 in Parkinson s Disease

- Company to highlight the 201 trial at multiple regional seminars for physicians - - Up to 61% of clinical sites actively screening patients by close of 2Q23 - BOSTON and ATLANTA, June 21, 2023. | June 21, 2023

United statesWestin southfieldLe meridiAlex loboMiltonh wernerMilton wernerInhibikase therapeutics incExchange commissionInhibikase or companyCompany contactSternir incInhibikase therapeuticsAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMilton wernerAlex loboMiltonh wernerLos angelesInhibikase therapeutics incSternir incCompany contactInhibikase or companyExchange commissionInhibikase therapeuticsAbelson tyrosine kinasesChief executive officerAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase.

United statesHoehn yahrMiltonh wernerAlex loboExchange commissionSternir incPrnewswire inhibikase therapeutics incInhibikase or companyCompany contactInhibikase therapeutics incAbelson tyrosine kinasesChief executive officerUpcoming milestonesClinical trialCompleted doseChronic myelogenous leukemia

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

BOSTON and ATLANTA, May 8, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of. | May 8, 2023

United statesMiltonh wernerAlex loboInhibikase or companyInhibikase therapeutics incPrnewswire inhibikase therapeutics incCompany contactSternir incAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophyInhibikase therapeuticsNc stock exchangePress releaseOurse ikt us45719w1062

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerAlex loboMilton wernerInhibikase therapeutics incCompany contactSternir incInhibikase or companyExchange commissionInhibikase therapeuticsAbelson tyrosine kinasesChief executive officerSidoti micro cap virtual conferenceSidoti micro cap virtualAbelson tyrosine kinaseAbleson tyrosine

vimarsana © 2020. All Rights Reserved.